Navigation Links
Cell Therapeutics Reports Second Quarter 2013 Financial Results
Date:7/31/2013

SEATTLE, July 31, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the second quarter and six months ended June 30, 2013.

"The second quarter was highlighted by the substantial progress we made in our reimbursement discussions for PIXUVRI® (pixantrone) in Europe, specifically in the UK and Italy," said James Bianco, M.D., President and CEO of CTI. "In particular, we look forward to our planned launch of PIXUVRI in Italy, where AIFA granted market access to bring this new approved therapy to patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed 2 or 3 prior regimens.  In addition, PERSIST-1, our randomized Phase 3 clinical trial designed to evaluate the safety and efficacy of pacritinib compared to best available therapy, excluding JAK inhibitors, continues to enroll patients with myelofibrosis.  A second planned Phase 3 trial is on track to initiate later this year."

Second Quarter 2013 and Recent HighlightsPIXUVRI® (pixantrone) Commercial:  Reimbursement Progress in Top European Markets

  • Received notice in July that market access in Italy was granted by the Italian Medicines Agency (AIFA) for PIXUVRI as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell NHL (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy). 
  • Received notice in July that the UK's Department of Health approved CTI's patient access scheme relating to PIXUVRI.  An independent appraisal committee of the National Institute for Health and Clinical Excellence (NICE) is scheduled to consider the new evidence on the cost effectiveness of PIXVURI at its meeting in September 2013.
  • Announced in May that Germany's Federal Joint Committee (G-BA) reported that additional benefit could not be determined for PIXUVRI versus the c
    '/>"/>

  • SOURCE Cell Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
    7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
    8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
    9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
    10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
    11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... company,s Bridgewater, New Jersey location ... Drug Administration (FDA) relating to an inspection in June ... Aesthetic injectable, which was divested to Galderma S.A. in ... Valeant,s contract manufacturers (rather than Valeant,s own internal manufacturing) ...
    (Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
    (Date:9/30/2014)... The report based on "Nutraceutical ... Growth and Forecast, 2007 - 2017," elaborated by Transparency ... billion in 2012 and is further expected to reach ... of 7.3% from 2012 to 2017. Nutraceutical ... especially to prevent chronic diseases that may occur to ...
    Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
    ... , REDWOOD CITY, Calif., Dec. 15 ... results from five new studies on its Onco type ... currently use to predict the likelihood of chemotherapy benefit and ... were presented at the 32nd Annual CTRC-AACR San Antonio Breast ...
    ... , , , WALTHAM, Mass., Dec. 15 Decision Resources, ... pharmaceutical and healthcare issues, finds that an overall survival benefit ... European oncologists in their decision to prescribe a novel agent ... The new Special European Physician & Payer Forum report entitled ...
    Cached Medicine Technology:Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 2For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 3
    (Date:9/30/2014)... 30, 2014Levothyroxine (L-T4), long the standard of care ... but some individuals do not regain optimal health ... may help to explain these differences. An expert ... thyroid hormone replacement reviewed the latest studies on ... whether a change to the current standard of ...
    (Date:9/30/2014)... at the University of Pittsburgh School of Dental Medicine ... the National Institute of Dental and Craniofacial Research, part ... exploration of the genetic roots of cleft lip and ... populations in Colombia, Nigeria, the Philippines and Pennsylvania. ... the lip or palate that can form when a ...
    (Date:9/30/2014)... muscles contain few stem cells, heart tissue is ... Now Tel Aviv University researchers are literally setting ... , Dr. Tal Dvir and his graduate student ... of Materials Science and Engineering, and Center for ... and nanotechnological tools ranging in size from ...
    (Date:9/30/2014)... a very valuable procedure by which to screen ... seems that healthy Americans who do undergo this ... before they actually should. Gina Kruse of ... advise that endoscopists stick to the national guidelines ... Journal of General Internal Medicine , published by ...
    (Date:9/30/2014)... SIMpalm, the top iPhone app development ... great social networking music sharing experience. Lyricz LLC officially ... and iPod touch®. The App allows users to take ... pre-populated ITunes account. This app also gives users the ... photo of their choice to the snippet of selected ...
    Breaking Medicine News(10 mins):Health News:New hypothyroidism treatment guidelines from American Thyroid Association 2Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:Americans undergo colonoscopies too often, study finds 2Health News:LYRICZ App for iPhone®, Helps You Share Images with Music to Inspire and Influence 2
    ... need in ... exploding HSA market, ... an online education, enrollment, and incentive support platform for,Group Health ... Health platform (http://www.fontishealth.com ) simplifies the,administration and use of ...
    ... The following is a,statement regarding Microsoft,s announcement of ... It is encouraging that companies like Microsoft, Google ... (PHR) products and systems,that people can use to manage ... follow suit. Having ready access to your own,health information ...
    ... tick-borne illness has nearly tripled, research shows , THURSDAY, Oct. ... fever in the United States almost tripled from 695 in ... fatal disease is caused by Rickettsia rickettsii bacteria, ... dog tick or Rocky Mountain wood tick. Within 14 days ...
    ... 4, 2007 MedImmune, Inc. today announced results from ... Society of America (IDSA) 45th Annual Meeting adding to ... RSV is a viral pathogen that produces annual ... manifests cold-like symptoms in healthy children, it can prove ...
    ... General,Dentistry (AGD) was extremely disappointed by President Bush,s ... Program (SCHIP),reauthorization bill. The SCHIP bill agreed upon ... important and beneficial dental,provisions intended to provide for ... Bush, who had threatened to veto this bill,followed ...
    ... Health Coaching Service,with HealthVault,s Best-Of-Breed Health ... and Compatibility with Other Related Devices,and ... LiveHealthier,announced today the compatibility of its ... HealthVault, the newly launched consumer health,platform. ...
    Cached Medicine News:Health News:Fontis Health Launches Online HSA Support System 2Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:Surge in U.S. Cases of Rocky Mountain Spotted Fever 2Health News:Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 3Health News:LiveHealthier Announces Its Health and Wellness Coaching Solution for Employer Groups is Now Compatible With Microsoft HealthVault 2
    Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
    ... technology allows the grasper ... a shorter length and ... the stone. The Unidex ... one-handed operation. Supplied sterile ...
    Bugbee Fulgurating...
    Fulgurating Electrode, 2 F...
    Medicine Products: